Synlogic

Historical price data

Synlogic Therapeutics is a clinical-stage biotech company developing Synthetic Biotics—engineered living microbes designed as targeted, orally administered therapeutics. The company's mission is to leverage synthetic biology to create transformative treatments for diseases with high unmet need, such as Phenylketonuria (PKU) and Homocystinuria (HCU). Its strategy involves advancing its modular platform through clinical proof-of-concept, though it currently faces significant financial and execution risks as a micro-cap public entity. Recent pipeline prioritization and workforce reductions reflect a focused but constrained operational strategy.

Proprietary Synthetic Biotic platform involving the genetic engineering of non-pathogenic bacterial strains (e.g., E. coli Nissle) with synthetic gene circuits to sense disease environments and produce therapeutic payloads locally within the gastrointestinal tract.

In HCU, Synlogic faces limited direct therapeutic competition but competes within the broader, emerging field of engineered live biotherapeutics. The company's distinct approach of extensive genetic engineering must now prove clinical success against a backdrop of significant skepticism following the PKU trial failure.